Thanks! You've successfully subscribed to the BONEZONE®/OMTEC® Monthly eNewsletter!

Please take a moment to tell us more about yourself and help us keep unwanted emails out of your inbox.

Choose one or more mailing lists:
BONEZONE/OMTEC Monthly eNewsletter
OMTEC Conference Updates
Advertising/Sponsorship Opportunities
Exhibiting Opportunities
* Indicates a required field.

2010 Company Financials: Orthopaedic and Spine


€28.4MM (~US $40.2MM), -14%

Orthobiologics $30.7MM, +34% (ORTHOVISC U.S. +32%, ex-U.S. -8%; MONOVISC in EU +126%)
4Q10 revenue: $8.4MM, +40% (U.S. +25%, ex-U.S. +96%; ORTHOVISC U.S. +25%, ex-U.S. +21%)

  • Requested review of MONOVISC via FDA’s orthopaedic advisory panel, no meeting date set yet

$15.4MM, +~109%
• Tissue Sales $15.2MM, +114%
• Royalties/Other $0.2MM, -30%
4Q10 revenue:
$5.3MM, +~141%
• Tissue Sales $5.2MM, +150%
• Royalties/Other $0.9MM, -88%

  • Secured ~$15MM in funding
  • OsteoSponge ~45%-50% of 2010 revenue
  • Launched OsteoSelect DBM Putty, OsteoSponge SC, hMatrix
  • Increased direct and indirect biologics sales force by >150% (includes 52 biologics sales reps, will grow to 64 by end of 2011)

Augment Bone Graft

  • ~650 patients enrolled in Augment clinical trials over 4 years
  • FDA orthopaedic advisory panel meeting confirmed for 5/11 to review premarket approval application
  • In Canada, transitioning from single exclusive distributor to network of >30 independent agents covering whole country
  • Presented preclinical study results demonstrating beneficial effects of technology on cartilage and bone repair in knee, effectiveness of rhPDGF-BB intra-tendon delivery for tendon repair
  • Announced results of preclinical study of interbody lumbar fusion in 2-level ovine model: Augment-treated specimens demonstrated highest fusion scores, showed equivalency to autograft